Primary navigation

    Admelog®

    Drug - Admelog® (insulin lispro) [Sanofi-Aventis U.S. LLC]

    July 2018

    Therapeutic area - Insulin

    Approval criteria

    • Patient is allergic to Humalog OR
    • Patient has an inadequate response to Humalog but has had a demonstrated adequate response to the Admelog OR
    • Patient is unable to change to Humalog due to a cognitive or developmental disability OR
    • Changing to Humalog would create undue hardship for the patient

    Quantity limits

    • 90 mL per 34 days

    Background

    Admelog is approved by the FDA under the New Drug Application (NDA) pathway and is not considered an interchangeable biosimilar to Humalog. Admelog is a rapid-acting human insulin analog indicated to improve glycemic control in adults and pediatric patients with type 1 diabetes mellitus and adults with type 2 diabetes mellitus

    Questions?

    MHCP Provider Call Center 651-431-2700 or 800-366-5411

    back to top